COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #97
Source   PDF   Share   Tweet
See all 181 studies
Late treatment study
Yu et al., Science China Life Sciences, 2020 Aug 3, doi:10.1007/s11427-020-1782-1 (Letter)
Beneficial effects exerted by hydroxych loroquine in treating COVID-19 patients via protecting multiple organs
Retrospective 2,882 patients in China, median age 62, 278 receiving HC Q, median 10 days post hospitalization, showing that HC Q treatment can reduce systemic inflammation and inhibit the cytokine storm, thus protecting multiple organs from inflammatory injuries, such as detoxification in the liver and attenuation of cardiac injury. IL-6 levels significantly reduced after HC Q treatment, p<0.05, and elevated after HC Q withdrawal. The significantly lower dose used here is potentially related to the different observations from the RECOVERY trial results. Authors suggest that treatment should be started as soon as possible.
Source   PDF   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.